Literature DB >> 14647251

Administration of granulocyte-colony-stimulating factor for allogeneic hematopoietic cell collection may induce the tissue factor-dependent pathway in healthy donors.

P Topcuoglu1, M Arat, K Dalva, M Ozcan.   

Abstract

The hypercoagulable state caused by the use of recombinant human granulocyte colony-stimulating factor (rhG-CSF) has been cited in anecdotal reports. Since tissue factor (TF) is the main initiator of the coagulation cascade, we examined if rhG-CSF had an inductive effect on the TF-dependent pathway in 18 healthy donors receiving rhG-CSF (10 microg/kg/day x 5 days) for peripheral blood progenitor cell mobilization. After rhG-CSF, there were increases both in TF antigen (TF:Ag) (P=0.01) and TF procoagulant activity (TF:PCA) (P=0.06) plasma levels and in TF:Ag cytofluorimetric expression on CD33 (+) cells (P=0.04). Mean activities of FVIII and vWF also increased significantly. Thrombin time was slightly prolonged (P=0.06) due to significant increases in plasma D-dimer levels. In addition, while FIX activity remained stable, there were marked reductions in mean plasma FX and FII activities and a slight decrease in FVII activity that resulted in a significant prolongation of prothrombin time within normal ranges. In conclusion, the administration of rhG-CSF led to a "prothrombotic state" via stimulation of TF and increased endothelial markers, such as F VIII and vWF. In the light of these findings, the use of rhG-CSF for stem cell mobilization should be undertaken cautiously in healthy donors with underlying thrombotic risk factors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14647251     DOI: 10.1038/sj.bmt.1704341

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  14 in total

1.  Granulocyte colony-stimulating factor.

Authors:  Kürsat Kaptan; Cengiz Beyan; Ahmet Ifran
Journal:  CMAJ       Date:  2006-10-24       Impact factor: 8.262

2.  PBSC collection from family donors in Japan: a prospective survey.

Authors:  Y Kodera; K Yamamoto; M Harada; Y Morishima; H Dohy; S Asano; Y Ikeda; T Nakahata; M Imamura; K Kawa; S Kato; M Tanimoto; Y Kanda; R Tanosaki; S Shiobara; S W Kim; K Nagafuji; M Hino; K Miyamura; R Suzuki; N Hamajima; M Fukushima; A Tamakoshi; J Halter; N Schmitz; D Niederwieser; A Gratwohl
Journal:  Bone Marrow Transplant       Date:  2013-09-30       Impact factor: 5.483

Review 3.  G-CSF in Healthy Allogeneic Stem Cell Donors.

Authors:  Kristina Hölig
Journal:  Transfus Med Hemother       Date:  2013-07-22       Impact factor: 3.747

Review 4.  A novel perspective on stem cell homing and mobilization: review on bioactive lipids as potent chemoattractants and cationic peptides as underappreciated modulators of responsiveness to SDF-1 gradients.

Authors:  M Z Ratajczak; C H Kim; A Abdel-Latif; G Schneider; M Kucia; A J Morris; M J Laughlin; J Ratajczak
Journal:  Leukemia       Date:  2011-09-02       Impact factor: 11.528

5.  Recommendations for managing the donation of haematopoietic stem cells from related and unrelated donors for allogeneic transplantation.

Authors:  Giuseppe Aprili; Alberto Bosi; Letizia Lombardini; Simonetta Pupella; Aurora Vassanelli
Journal:  Blood Transfus       Date:  2013-01-23       Impact factor: 3.443

6.  Administration of granulocyte colony stimulating factor after liver transplantation leads to an increased incidence and severity of ischemic biliary lesions in the rat model.

Authors:  Olaf Dirsch; Haidong Chi; Yuan Ji; Yan Li Gu; Christoph E Broelsch; Uta Dahmen
Journal:  World J Gastroenterol       Date:  2006-08-21       Impact factor: 5.742

Review 7.  Effects and safety of granulocyte colony-stimulating factor in healthy volunteers.

Authors:  Paolo Anderlini
Journal:  Curr Opin Hematol       Date:  2009-01       Impact factor: 3.284

8.  Stem cell collection in unmanipulated HLA-haploidentical/mismatched related transplantation with combined granulocyte-colony stimulating factor-mobilised blood and bone marrow for patients with haematologic malignancies: the impact of donor characteristics and procedural settings.

Authors:  C Zhang; X-H Chen; X Zhang; L Gao; L Gao; P-Y Kong; X-G Peng; A-H Sun; Y Gong; D-F Zeng; Q-Y Wang
Journal:  Transfus Med       Date:  2010-02-01       Impact factor: 2.019

Review 9.  Allogeneic peripheral blood stem cell collection as of 2008.

Authors:  Beverly Rhodes; Paolo Anderlini
Journal:  Transfus Apher Sci       Date:  2008-05-22       Impact factor: 1.764

10.  Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation.

Authors:  Michael A Pulsipher; Pintip Chitphakdithai; Brent R Logan; Willis H Navarro; John E Levine; John P Miller; Bronwen E Shaw; Paul V O'Donnell; Navneet S Majhail; Dennis L Confer
Journal:  Blood       Date:  2014-04-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.